The progression-free survival (PFS) rate at 5 years improved from 40.8% with active monitoring and no disease-specific ...

Ciltacabtagene autoleucel achieved a 100% complete response rate in patients with high-risk smoldering multiple myeloma, as ...

In the past, you had to have organ damage, as shown by CRAB criteria, to be diagnosed with multiple myeloma. CRAB is an acronym that stands for the signs on blood tests and imaging your doctor ...

The phase 3 AQUILA study showed a 63.1% progression-free rate at 5 years with daratumumab versus 40.8% with active monitoring ...

The risk for disease progression or death was reduced by 51% with subcutaneous Darzalex Faspro in certain patients with ...

Treatment with subcutaneous daratumumab significantly improved progression-free survival in patients with intermediate- or high-risk smoldering multiple myeloma.

A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition can progress to active multiple myeloma, a type of blood cancer.

Primary results from the phase 3 AQUILA study showed that subcutaneous daratumumab elicited a significant improvement in PFS ...